Allogene (NASDAQ: ALLO) SVP Finance granted options, RSUs and sells shares

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. SVP Finance Annie Yoshiyama reported new equity awards and a small tax-related share sale. On February 2, 2026, she received a stock option for 179,691 shares of common stock at an exercise price of $1.87 per share and an award of 50,827 restricted stock units (RSUs). The option vests 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments, while the RSUs vest in four equal annual installments starting from February 2, 2026, subject to continued service. On the same date, she sold 4,167 shares of common stock at a weighted average price of $1.72 solely to cover tax withholding on vesting RSUs, under a mandatory “sell to cover” arrangement, and reported owning 130,322 common shares directly afterward.

Insider Trade Summary

Net Seller: 4,167 shares ($7,167)

Net Sell 3 txns

Insider Yoshiyama Annie

Role SVP, Finance

Sold 4,167 shs ($7K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	179,691	$0.00	--
Grant/Award	Restricted Stock Unit	50,827	$0.00	--
Sale	Common Stock	4,167	$1.72	$7K

Holdings After Transaction: Stock Option (Right to buy) — 179,691 shares (Direct); Restricted Stock Unit — 50,827 shares (Direct); Common Stock — 130,322 shares (Direct)

Footnotes (1)

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Includes 3,826 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yoshiyama Annie

(Last) (First) (Middle)

210 EAST GRAND AVE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		4,167(1)	D	$1.72(2)	130,322(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.87	02/02/2026		A		179,691		(4)	02/02/2036	Common Stock	179,691	$0	179,691	D
Restricted Stock Unit	(5)	02/02/2026		A		50,827		(5)	(5)	Common Stock	50,827	$0	50,827	D

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. Includes 3,826 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program.

4. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

5. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Allogene (ALLO) SVP Finance Annie Yoshiyama report on February 2, 2026?

She reported three transactions: a stock option grant for 179,691 shares, an award of 50,827 RSUs, and a sale of 4,167 common shares at a weighted average price of $1.72 to cover tax withholding obligations.

Were the Allogene (ALLO) shares sold by Annie Yoshiyama a discretionary sale?

The 4,167 shares of Allogene common stock were sold solely to cover tax withholding on vesting RSUs. The sale was mandated by the company’s equity incentive plan as a “sell to cover” transaction and was not a discretionary trade by the reporting person.

What are the terms of Annie Yoshiyama’s new stock option grant at Allogene (ALLO)?

She received a stock option for 179,691 shares of Allogene common stock at an exercise price of $1.87. 25% vests on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to continued service.

How do Annie Yoshiyama’s restricted stock units (RSUs) at Allogene (ALLO) vest?

She was granted 50,827 RSUs, each representing one share of Allogene common stock. These RSUs vest in four equal annual installments over four years from February 2, 2026, provided she continues service through each vesting date.

How many Allogene (ALLO) common shares does Annie Yoshiyama own after these transactions?

Following the February 2, 2026 transactions, Annie Yoshiyama reported beneficial ownership of 130,322 shares of Allogene common stock held directly. This figure includes 3,826 shares previously acquired through an employee stock purchase program.

What is Annie Yoshiyama’s role at Allogene Therapeutics (ALLO) according to this Form 4?

The Form 4 lists Annie Yoshiyama as an officer of Allogene Therapeutics with the title SVP, Finance. She is not identified as a director or 10% owner, and the filing is made by a single reporting person.